$INSM Cashflow Statement | Understand Stock

$INSM

$94.96 +$1.63 (1.75%) Close

$INSM Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation
Amortization of intangible assets
Stock-based compensation expense
Loss on extinguishment of debt
Amortization of debt issuance costs and accretion of debt discount
Accretion of debt discount
Amortization of debt issuance costs
Paid-in-kind interest capitalized
Royalty financing non-cash interest expense
Accretion of discount on marketable securities, net
Finance lease amortization expense
Non-cash operating lease expense
Change in fair value of deferred and contingent consideration liabilities
Change in fair value of interest rate swap
Vertuis/Adrestia acquisition
Vertuis Bio, Inc.
Adrestia Therapeutics Ltd
Changes in operating assets and liabilities:
Accounts receivable
Inventory
Prepaid expenses and other current assets
Other assets
Accounts payable and accrued liabilities
Other liabilities
Net cash used in operating activities

Investing activities
Purchase of fixed assets
Payment of AZ milestone
Purchase of marketable securities
Cash acquired in asset acquisition
Cash paid for Business Acquisition, net
PARI milestone upon regulatory approvals
Maturities of marketable securities
Net cash used in investing activities

Financing activities
Proceeds from exercise of stock options and ESPP
Proceeds from issuance of common stock, net
Payment on extinguishment of 1.75% convertible senior notes due 2025
Proceeds from issuance of Term Loan
Proceeds from issuance Royalty Financing Agreement
Payments of principal of 0.75% convertible senior notes due 2028
Proceeds from issuance of 0.75% convertible senior notes due 2028
Payment of debt issuance costs
Payments of finance lease principal
Net cash provided by financing activities
Effect of exchange rates on cash and cash equivalents
Net (decrease) increase in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Supplemental disclosures of cash flow information:
Cash paid for interest
Cash paid for income taxes

Comments